Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyramax in mild to moderate COVID-19
NCT05084911Phase 3Completed
- Sponsor
- Shinpoong Pharma
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of pyronaridine in coronavirus disease 2019 (COVID-19), sponsored by Shinpoong Pharma. Started Oct 2021; status: completed.
02
Drugs
pyronaridine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05084911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084911.